Ribociclib (LEE011)

For research use only.

Catalog No.S7440

54 publications

Ribociclib (LEE011) Chemical Structure

CAS No. 1211441-98-3

Ribociclib (LEE011) is an orally available, and highly specific inhibitor of CDK4 and CDK6 with IC50 of 10 nM and 39 nM. Phase 3.

Size Price Stock Quantity  
10mM (1mL in DMSO) USD 297 In stock
USD 197 In stock
USD 297 In stock
USD 590 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Selleck's Ribociclib (LEE011) has been cited by 54 publications

Purity & Quality Control

Choose Selective CDK Inhibitors

Biological Activity

Description Ribociclib (LEE011) is an orally available, and highly specific inhibitor of CDK4 and CDK6 with IC50 of 10 nM and 39 nM. Phase 3.
Features Orally bioavailable CDK4/6-selective inhibitor that has been tested in Phase III clinical trials for treatment of advanced breast cancer.
Targets
CDK4 [2]
(Cell-free assay)
CDK6 [2]
(Cell-free assay)
10 nM 39 nM
In vitro

LEE011, as dual CDK4/CDK6 inhibitor, significantly inhibits the growth of 12 of 17 neuroblastoma cell lines with mean IC50 of 307 nM. The growth inhibition of neuroblastoma cell lines is primarily cytostatic and is mediated by a G1 cell-cycle arrest and cellular senescence. [1]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
DFSP105 NGH3ZXhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3z5fVI1KGh? MnftS2k2OD1{N{[gcm0> NIHnWlU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUi1NlA2QCd-MkW4OVIxPTh:L3G+
Myoblast M{XK[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFXaNHY4OiCq NXjnTGlWUUN3ME2xNFM2KG6P NXPZW2RjRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW4NVA{PzVpPkK1PFExOzd3PD;hQi=>
IMRS NGPTSHdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVnBdJczPzJiaB?= M2jnbWlEPTB;OEezJI5O NXSxOY54RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW4NVA{PzVpPkK1PFExOzd3PD;hQi=>
SKNAS NYPkb29lT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2HtOlczKGh? NW\HVWw3UUN3MP-8olExODByIH7N MmDnQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV6MUCzO|UoRjJ3OEGwN|c2RC:jPh?=
Rh28 M4TnbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3\iWlczKGh? NHr5fIdKSzVyPUi0OUBvVQ>? Mn7tQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV6MUCzO|UoRjJ3OEGwN|c2RC:jPh?=
Rh41 M3rXVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmDhO|IhcA>? Mke4TWM2OD15MUi3JI5O NWDyRVF{RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW4NVA{PzVpPkK1PFExOzd3PD;hQi=>
CW9019 NInaOG1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFXNU5E4OiCq Mmf3TWM2OD17OUGyJI5O M1nodVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3OEGwN|c2Lz5{NUixNFM4PTxxYU6=
Rh5 NUnGSWcxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWq3NkBp NIixWJpKSzVy78{eNVAxODBibl2= NXfvW|ZTRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW4NVA{PzVpPkK1PFExOzd3PD;hQi=>
Rh30 NV;qRYh1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVn0bFJJPzJiaB?= NGjWN2JKSzVy78{eNVAxODBibl2= Mlq1QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV6MUCzO|UoRjJ3OEGwN|c2RC:jPh?=
778 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXrJUGsxPzJiaB?= NH3GPXlqdmirYnn0d{Bk\WyuIHfyc5d1cCCmb4PlJIRmeGWwZHXueIx6 M3LUUVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3MEK4OFY6Lz5{NUCyPFQ3QTxxYU6=
449 MmfSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUXMR3QzPzJiaB?= Ml;ibY5pcWKrdIOgZ4VtdCCpcn;3eIgh\G:|ZTDk[ZBmdmSnboTsfS=> NGG0[409[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUCyPFQ3QSd-MkWwNlg1Pjl:L3G+
LP3 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXfqbpBIPzJiaB?= MXHpcohq[mm2czDj[YxtKGe{b4f0bEBld3OnIHTldIVv\GWwdHz5 MoPoQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjVyMki0OlkoRjJ3MEK4OFY6RC:jPh?=
LP6 NHroWm1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUXOZmJ{PzJiaB?= NYDDdo1lcW6qaXLpeJMh[2WubDDndo94fGhiZH;z[UBl\XCnbnTlcpRtgQ>? MoDkQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjVyMki0OlkoRjJ3MEK4OFY6RC:jPh?=
LP8 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXHu[HFbPzJiaB?= MoWybY5pcWKrdIOgZ4VtdCCpcn;3eIgh\G:|ZTDk[ZBmdmSnboTsfS=> Mn;yQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjVyMki0OlkoRjJ3MEK4OFY6RC:jPh?=
LPS141 MnL6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVf6[|ZnPzJiaB?= M4T0W4lvcGmkaYTzJINmdGxiZ4Lve5RpKGSxc3Wg[IVx\W6mZX70cJk> NX:wR483RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWwNlg1PjlpPkK1NFI5PDZ7PD;hQi=>
778 MmLhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3T6WFMvOzNizszN MWKyOEBp NXPtNJFQ\GWlcnXhd4V{KHSqZTDwdo9xd3K2aX;uJI9nKGOnbHzzJIlvKFNicHjhd4U> M3OxWFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3MEK4OFY6Lz5{NUCyPFQ3QTxxYU6=
449 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4XMd|MvOzNizszN MnrlNlQhcA>? NVWwZllY\GWlcnXhd4V{KHSqZTDwdo9xd3K2aX;uJI9nKGOnbHzzJIlvKFNicHjhd4U> NVqzU|BoRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWwNlg1PjlpPkK1NFI5PDZ7PD;hQi=>
LP3 NXThc5pLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUmzMlM{KM7:TR?= MlzRNlQhcA>? NH\4dHdl\WO{ZXHz[ZMhfGinIIDyc5BwenSrb36gc4Yh[2WubIOgbY4hWyCyaHHz[S=> MnPSQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjVyMki0OlkoRjJ3MEK4OFY6RC:jPh?=
LP6 NYPjSphIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkPwN{4{OyEQvF2= MX6yOEBp MmC1[IVkemWjc3XzJJRp\SCycn;wc5J1cW:wIH;mJINmdGy|IHnuJHMheGijc3W= MY[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTB{OES2PUc,OjVyMki0Olk9N2F-
LP8 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1zwU|MvOzNizszN NV\Hd3VNOjRiaB?= NGfLfVNl\WO{ZXHz[ZMhfGinIIDyc5BwenSrb36gc4Yh[2WubIOgbY4hWyCyaHHz[S=> M2ToUVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3MEK4OFY6Lz5{NUCyPFQ3QTxxYU6=
LPS141 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVOwVo0{Oy5|MzFOwG0> MmfrNlQhcA>? NVXvUlZV\GWlcnXhd4V{KHSqZTDwdo9xd3K2aX;uJI9nKGOnbHzzJIlvKFNicHjhd4U> MknpQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjVyMki0OlkoRjJ3MEK4OFY6RC:jPh?=
IMR5 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4T6XlI1KGh? M2jtR2ROW09? MkfZTWM2OD1zMk[gcm0> MWi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDB2NUG3PUc,OjRyNEWxO|k9N2F-
BE2C MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1jNZ|I1KGh? MoPqSG1UVw>? M1rqUmlEPTB;MUO0JI5O M1rTS|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2MES1NVc6Lz5{NEC0OVE4QTxxYU6=
1643 MmS3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFnyZZMzPCCq NELu[3pFVVOR NXfI[WhXUUN3ME2xOFchdk1? NGm4SWU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEC0OVE4QSd-MkSwOFUyPzl:L3G+
SKNSH MoqzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUfOVVhrOjRiaB?= MYrEUXNQ MVTJR|UxRTF2ODDuUS=> NX3y[mdSRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSwOFUyPzlpPkK0NFQ2OTd7PD;hQi=>
SY5Y MlrSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoDzNlQhcA>? NUj3eVVRTE2VTx?= M3H1T2lEPTB;MUW0JI5O MWG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDB2NUG3PUc,OjRyNEWxO|k9N2F-
NGP M1z1Xmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MorXNlQhcA>? MoPwSG1UVw>? NXPUV2N2UUN3ME2xO|Uhdk1? NGfSNHM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEC0OVE4QSd-MkSwOFUyPzl:L3G+
KELLY NEC1VY1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn:4NlQhcA>? M1u3[WROW09? NVLMbYhOUUN3ME2yNlAhdk1? MVu8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDB2NUG3PUc,OjRyNEWxO|k9N2F-
CHP134 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmC3NlQhcA>? M1L2O2ROW09? NF;JSldKSzVyPUK3N{BvVQ>? NG\vcpQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEC0OVE4QSd-MkSwOFUyPzl:L3G+
NLF MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHrKN2wzPCCq NXq1SZp6TE2VTx?= NUfN[oNbUUN3ME2zNlghdk1? MV[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDB2NUG3PUc,OjRyNEWxO|k9N2F-
LAN5 M3zRTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUDGeYNlOjRiaB?= MXzEUXNQ MU\JR|UxRTR{OTDuUS=> MXe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDB2NUG3PUc,OjRyNEWxO|k9N2F-
NB69 NEfXR|VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIm0XZIzPCCq NXXhToxnTE2VTx?= NIOxNXBKSzVyPUezPEBvVQ>? M3fmPFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2MES1NVc6Lz5{NEC0OVE4QTxxYU6=
SKNDZ MnnCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmHKNlQhcA>? NH\vTXFFVVOR NUTDSnh5UUN3ME24NFEhdk1? NX\DVXFMRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSwOFUyPzlpPkK0NFQ2OTd7PD;hQi=>
NBSD MmjXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX61Sm9pOjRiaB?= NYnxPVRXTE2VTx?= NHz3R3NKSzVyPUG5NFAhdk1? NGT3V2w9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEC0OVE4QSd-MkSwOFUyPzl:L3G+
SKNF1 M1TleWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnTpNlQhcA>? MoXYSG1UVw>? MmjOTWM2OD1|NUCwJI5O NYjJOYVnRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSwOFUyPzlpPkK0NFQ2OTd7PD;hQi=>
EBC1 MnnCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEX4bmwzPCCq NEf1RVlFVVOR MYjJR|UxRTZ2MECgcm0> Ml;GQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjRyNEWxO|koRjJ2MES1NVc6RC:jPh?=
SKNAS NVLFV48xT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEjyUJczPCCq M3H4OmROW09? M325[WlEPTExvK6xNFAxOCCwTR?= Ml;zQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjRyNEWxO|koRjJ2MES1NVc6RC:jPh?=
NB16 MnTUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGHXbWUzPCCq NF22TWZFVVOR MkHZTWM2OO,:nkGwNFAxKG6P MmLDQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjRyNEWxO|koRjJ2MES1NVc6RC:jPh?=
RPE1 NIL5fGhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYqyOEBp M1e3T2ROW09? MlGwTWM2OO,:nkGwNFAxKG6P NIe2OHY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEC0OVE4QSd-MkSwOFUyPzl:L3G+
Sf21 NHzXTYtHfW6ldHnvckBie3OjeR?= NIXjOmQyOCCvaX7z NXPhXlFFUW6qaXLpeIlwdiCxZjDy[YNwdWKrbnHueEBpfW2jbjDmeYxtKGynbnf0bEBPNXSncn3pcoFtKEeVVD30ZYdo\WRiQ1TLOE9EgWOuaX6tSFMh[29vZYjwdoV{e2WmIHnuJIJi[3Wub4\pdpV{KGmwZnXjeIVlKHOoMkGgZ4VtdHNidYPpcochWmJic4Xid5Rz[XSnIHnuJJBz\XOnbnPlJI9nKFupYX3tZVM{WF2DVGCgZYZ1\XJiMUCgcYlveyCkeTDzZ4lvfGmubHH0bY9vKGOxdX70bY5oKG2ndHjv[EwhUUN3MDC9JFAvODF|IN88UU4> NY\aU2gxRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm1NVg{OTJpPkK5OVE5OzF{PD;hQi=>
Sf21 MmjnSpVv[3Srb36gZZN{[Xl? NVzvSXlbOTBibXnudy=> M13HcGlvcGmkaYTpc44hd2ZicnXjc41jcW6jboSgbJVu[W5iZoXscEBt\W6pdHigR{11\XKvaX7hcEA3UGm|LYTh[4dm\CCFRFu5M2N6[2yrbj3UNUBkdy2neIDy[ZN{\WRiaX6gZoFkfWyxdnnyeZMhcW6oZXP0[YQhe2Z{MTDj[YxteyC3c3nu[{BRTEu2aXTlJJN2[nO2cnH0[UBqdiCycnXz[Y5k\SCxZjDb[4FudWF|M2DdRXRRKGGodHXyJFExKG2rboOgZpkhe2OrboTpcIxifGmxbjDjc5VvfGmwZzDt[ZRpd2RuIFnDOVAhRSByLkG5O{DPxE1w MofkQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl3MUizNVIoRjJ7NUG4N|EzRC:jPh?=
HepG2 NX;TeHdLSW62aYDyc4xq\mW{YYTpeoUh[XO|YYm= MYS3NkBpenN? NGLHN5BCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFjldGczKGOnbHzzJIFnfGW{IEeyJIhzeyCkeTDD[YxVcXSncj3HcI8h[XO|YYmsJGVEPTBiPTCwMlI5PjJizszNMi=> MXK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTRyN{m3OUc,Ojl2MEe5O|U9N2F-
SEM NESyZZlCdnSrcILvcIln\XKjdHn2[UBie3OjeR?= MkHyO|IhcHK| MonrRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDoeY1idiCVRV2gZ4VtdHNiYX\0[ZIhPzJiaILzJIJ6KEOnbGTpeIVzNUeubzDhd5NigSxiRVO1NEA:KDBwNE[wOUDPxE1w NUjtcXRJRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0NFc6PzVpPkK5OFA4QTd3PD;hQi=>
KOPN8 M{\ncGFvfGmycn;sbYZmemG2aY\lJIF{e2G7 NYnSVZAxPzJiaILz MXHBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKEuRUF64JINmdGy|IHHmeIVzKDd{IHjyd{BjgSCFZXzUbZRmei2JbH:gZZN{[XluIFXDOVAhRSByLkWwNFgh|ryPLh?= NYXOd|dGRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0NFc6PzVpPkK5OFA4QTd3PD;hQi=>
NCI-H1299 Ml\OR5l1d3SxeHnjbZR6KGG|c3H5 NWLSe|NGPzJiaILz MmHER5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gUmNKNUhzMkm5JINmdGy|IHHzd4V{e2WmIHHzJJJm\HWldHnvckBqdiClZXzsJJZq[WKrbHn0fUBi\nSncjC3NkBpenNiYomgR2NMQCCjc4PhfUwhUUN3MDC9JFUvPDZizszNMi=> M33XVVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NUG4N|EzLz5{OUWxPFMyOjxxYU6=
T47D NXS3SVFzT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= M2iz[|czKGi{cx?= NUXwTmlqT3Kxd4ToJIlvcGmkaYTpc44hd2ZiaIXtZY4hXDR5RDDj[YxteyCrbnP1ZoF1\WRiZn;yJFczKGi{czDifUBES0t6IHHzd4F6NCCLQ{WwJF0hPi5{Mkeg{txONg>? M3LvPFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6NkWxPVc6Lz5{OE[1NVk4QTxxYU6=
T47D M2jMbGN6fG:2b4jpZ4l1gSCjc4PhfS=> NGLWOXI4OiCqcoO= NVrUO3V5S3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hXDR5RDDj[YxteyCjc4Pld5Nm\CCjczDy[YR2[3Srb36gbY4h[2WubDD2bYFjcWyrdImgZYZ1\XJiN{KgbJJ{KGK7IFPDT|gh[XO|YYmsJGlEPTBiPTC2MlI{KM7:TT6= NIO3bJc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUWxPFMyOid-Mkm1NVg{OTJ:L3G+
H1299 M{\VTGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NGHoTYM4OiCqcoO= MWrHdo94fGhiaX7obYJqfGmxbjDv[kBpfW2jbjDINVI6QSClZXzsd{BqdmO3YnH0[YQh\m:{IEeyJIhzeyCkeTDDR2s5KGG|c3H5MEBKSzVyIE2gO{43OzdizszNMi=> M2jtdFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6NkWxPVc6Lz5{OE[1NVk4QTxxYU6=
KOPN8 MonyRZBweHSxc3nzJIF{e2G7 M3nOUFAvPSC3TR?= MlTaN{BpenN? MmXCTY5lfWO2aX;uJI9nKGGyb4D0c5NqeyCrbjDoeY1idiCNT2DOPEBk\WyuczDhd5Nme3OnZDDhd{B2eHKnZ4XsZZRqd25ib3[gZ4xm[X[nZDDQRXJRKGyndnXsJIF1KDBwNTD1UUBi\nSncjCzJIhzeyCkeTDX[ZN1\XKwIHLsc5Qh[W6jbInzbZM> MoHjQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2MEe5O|UoRjJ7NEC3PVc2RC:jPh?=
KOPN8 NFPyZ5pCeG:ydH;zbZMh[XO|YYm= NVPwd4xpOC53IIXN NU[0fHE{OjRiaILz MoPjTY5lfWO2aX;uJI9nKGGyb4D0c5NqeyCrbjDoeY1idiCNT2DOPEBk\WyuczDhd5Nme3OnZDDhd{B2eHKnZ4XsZZRqd25ib3[gZ4xm[X[nZDDQRXJRKGyndnXsJIF1KDBwNTD1UUBxemVvdILlZZRm\CC5aYToJG5CSyCob4KgNUBpeiCjbnSgcYVie3W{ZXSgZYZ1\XJiMkSgbJJ{KGK7IGfld5Rmem5iYnzveEBidmGueYPpdy=> MlTOQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2MEe5O|UoRjJ7NEC3PVc2RC:jPh?=
Hep3B NF\POZFE\WyuIHP5Z4xmKGG|c3H5 M37xO|I1KGi{cx?= NX7Gepg{S2WubDDjfYNt\SCjcoLld5QhcW5iaIXtZY4hUGWyM1KgZ4VtdHNiYYPz[ZN{\WRiYYOgZYNkfW23bHH0bY9vKGG2IFewM2cyKHCqYYPlJIFnfGW{IEK0JIhzeyCkeTDwdo9xcWSrdX2gbY9lcWSnIIP0ZYlvcW6pIHLhd4VlKG[ub4egZ5l1d22ndIL5 M1fSNlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NUG4N|EzLz5{OUWxPFMyOjxxYU6=
HepG2 NXTuWIZuS2WubDDjfYNt\SCjc4PhfS=> MmPENlQhcHK| NH7nV|NE\WyuIHP5Z4xmKGG{cnXzeEBqdiCqdX3hckBJ\XCJMjDj[YxteyCjc4Pld5Nm\CCjczDhZ4N2dXWuYYTpc44h[XRiR{CvS|EheGijc3WgZYZ1\XJiMkSgbJJ{KGK7IIDyc5Bq\Gm3bTDpc4Rq\GVic4ThbY5qdmdiYnHz[YQh\myxdzDjfZRwdWW2com= NFXWVYM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUWxPFMyOid-Mkm1NVg{OTJ:L3G+
A549 M1XjR2NmdGxiY4njcIUh[XO|YYm= M4rtd|I1KGi{cx?= NG\1d4xE\WyuIHP5Z4xmKGG{cnXzeEBqdiCqdX3hckBCPTR7IHPlcIx{KGG|c3Xzd4VlKGG|IHHjZ5VufWyjdHnvckBifCCJMD;HNUBxcGG|ZTDh[pRmeiB{NDDodpMh[nlicILvdIllcXWvIHnv[Ill\SC|dHHpcolv\yCkYYPl[EBndG:5IHP5eI9u\XS{eR?= M4ewOVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NUG4N|EzLz5{OUWxPFMyOjxxYU6=
NCI-H460 MnXSR4VtdCCleXPs[UBie3OjeR?= NEK3XmUzPCCqcoO= M4W3VGNmdGxiY4njcIUh[XK{ZYP0JIlvKGi3bXHuJG5EUS2KNE[wJINmdGy|IHHzd4V{e2WmIHHzJIFk[3WvdXzheIlwdiCjdDDHNE9IOSCyaHHz[UBi\nSncjCyOEBpenNiYomgdJJweGmmaYXtJIlw\GmmZTDzeIFqdmmwZzDiZZNm\CCobH;3JIN6fG:vZYTyfS=> M1vYflxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NUG4N|EzLz5{OUWxPFMyOjxxYU6=
T47D MVfD[YxtKGO7Y3zlJIF{e2G7 MXKyOEBpenN? NG\Nem9E\WyuIHP5Z4xmKGG{cnXzeEBqdiCqdX3hckBVPDeGIHPlcIx{KGG|c3Xzd4VlKGG|IHHjZ5VufWyjdHnvckBifCCJMD;HNUBxcGG|ZTDh[pRmeiB{NDDodpMh[nlicILvdIllcXWvIHnv[Ill\SC|dHHpcolv\yCkYYPl[EBndG:5IHP5eI9u\XS{eR?= MonHQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl3MUizNVIoRjJ7NUG4N|EzRC:jPh?=
MDA-MB-231 M4DLT2NmdGxiY4njcIUh[XO|YYm= M3r4UVI1KGi{cx?= NV2xXIFqS2WubDDjfYNt\SCjcoLld5QhcW5iaIXtZY4hVUSDLV3CMVI{OSClZXzsd{Bie3Onc4Pl[EBieyCjY3P1cZVt[XSrb36gZZQhTzBxR{GgdIhie2ViYX\0[ZIhOjRiaILzJIJ6KHC{b4Dp[Il2dSCrb3Tp[IUhe3SjaX7pcoch[mG|ZXSg[oxwfyCleYTvcYV1enl? NVXaWJdlRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm1NVg{OTJpPkK5OVE5OzF{PD;hQi=>
Fluc-labeled 4T1 NUjTVYFwSW62aYT1cY9zKGG|c3H5 MV:xN|AhdWdxa3e= MXOxPEBl[Xm| MkTSRY51cXS3bX;yJIFkfGm4aYT5JIFo[Wmwc4SgcY92e2ViRnz1Z{1t[WKnbHXkJFRVOSClZXzsd{BqdXCuYX70[YQhcW5iQnHsZk9kKG2xdYPlJIF{e2W|c3XkJIF{KHKnZIXjeIlwdiCrbjD0eY1weiC5ZXnnbJQh[XRiMUOwJI1oN2upLDDpdEBi\G2rbnnzeIVz\WRiZHHpcJkh\m:{IEG4JIRigXNibXXhd5Vz\WRiYX\0[ZIhQCC2bzCyOUBl[Xm| M4r3flxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NUG4N|EzLz5{OUWxPFMyOjxxYU6=
T47D NHnWb5RE\WyuIHP5Z4xmKGG|c3H5 NVzJPHlJOjRiaILz NYfkNoc3UW6mdXP0bY9vKG:oIHPlcIwh[3mlbHWgZZJz\XO2IHnuJIh2dWGwIGS0O2Qh[2WubIOgZZN{\XO|ZXSgZZMhcW6lcnXhd4UhcW5iR{CvS|EheGijc3WgZYNkfW23bHH0bY9vKGmwY4XiZZRm\CCob4KgNlQhcHK|IHL5JIZtd3diY4n0c41mfHK7 M1KyVVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6NkWxPVc6Lz5{OE[1NVk4QTxxYU6=

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
pRb(S807) / Rb / p53 / Cyclin E / Cyclin D1 / CDK4 / CDK6 / p27 / p21 / PARP; 

PubMed: 29789630     


Effect of ribociclib on pRB and G1 cell cycle regulating protein expressions in C666-1 and HK1 cells. Cells were treated with ribociclib in 2 concentrations, one of them near their corresponding IC50, for 24 and 48 hours. Phosphorylation of Rb in all cell䲧疝Ỵ疞㧀疜膉痘 瘿뾠ՂᾰƌՂĀ 㺣痖帉痖Ѐ瑖堘𢡄빢᎒ՂĀ鑸᎒彿堙奋堙巫堙᎒ﻺ᎒彿堙ﻮ᎒塚堙ﻺ᎒ꍈ堞빢᎒學堙漸堞圔堙빢᎒圞堙圭堙𢡄玚Wᾰƌ ᾰƌ戤瘯Ɖ⟸෕䐺痖暼瘿⟸෕ᾰƌ ⟸෕Ð㺣痖⟸෕€𢡄⟼෕€䀷痗⟼෕౴⟼෕

29789630
Growth inhibition assay
Cell viability ; 

PubMed: 26390342     


Effects of palbociclib and ribociclib on viability of H157, H2170, H520 and H596 cells after 72 hours of drug treatment and IC50 values for inhibition of cell viability.

26390342
In vivo

LEE011 (200 mg/kg daily, p.o.) significantly causes tumor growth delay in mice harboring the BE2C or 1643 xenografts with no weight loss or other signs of toxicity. [1]

Protocol

Cell Research:

[1]

- Collapse
  • Cell lines: BE2C, IMR5, 1643, SY5Y, CHP134, SKNSH, NGP, KELLY, LAN5, NLF, NB69, SKNDZ, NBSD, NBLS, SKNFI, EBC1, SKNAS, NB16, RPE1 cell lines.
  • Concentrations: 10 μM
  • Incubation Time: ~100 hours
  • Method:

    A panel of neuroblastoma cell lines, selected based upon prior demonstration of substrate adherent growth, is plated in triplicate on the Xcelligence Real-Time Cell Electronic Sensing system and treated 24 hours later with a four-log dose range of inhibitor or with a dimethyl sulfoxide (DMSO) control. Cell indexes are monitored continuously for ~100 hours, and IC50 values are determined as follows: growth curves are generated by plotting the cell index as a function of time and are normalized to the cell index at the time of treatment for a baseline cell index of 1. The area under the normalized growth curve from the time of treatment to 96 hours posttreatment is then calculated using a baseline area of 1 (the cell index at the time of treatment). Areas are normalized to the DMSO control, and the resulting data are analyzed using a nonlinear log inhibitor versus normalized response function. All experiments are repeated at least once.


    (Only for Reference)
Animal Research:

[1]

- Collapse
  • Animal Models: Mice bearing BE2C, NB-1643, or EBC1 xenografts.
  • Dosages: ~200 mg/kg daily
  • Administration: p.o.
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 7 mg/mL (16.1 mM)
Water Insoluble
Ethanol Insoluble

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 434.54
Formula

C23H30N8O

CAS No. 1211441-98-3
Storage powder
in solvent
Synonyms N/A
Smiles CN(C)C(=O)C1=CC2=CN=C(N=C2N1C3CCCC3)NC4=NC=C(C=C4)N5CCNCC5

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Dosage mg/kg Average weight of animals g Dosing volume per animal ul Number of animals
Step 2: Enter the in vivo formulation ()
% DMSO % % Tween 80 % ddH2O
CalculateReset

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and SDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT04657679 Recruiting Drug: Ribociclib Breast Cancer Georgetown University|Medstar Health Research Institute|Breast Cancer Research Foundation|Georgetown-Howard Universities Center for Clinical and Translational Science (GHUCCTS) March 2021 --
NCT04315233 Recruiting Drug: Ribociclib|Drug: Belinostat Metastatic Breast Cancer|Recurrent Ovarian Carcinoma University of Utah|Novartis|Acrotech Biopharma October 29 2020 Phase 1
NCT03834740 Recruiting Drug: Ribociclib|Drug: Everolimus Glioblastoma Multiforme|Glioma of Brain St. Joseph''s Hospital and Medical Center Phoenix|Ivy Brain Tumor Center|Barrow Neurological Institute December 21 2018 Early Phase 1
NCT03701334 Active not recruiting Drug: Ribociclib|Other: Endocrine Therapy Early Breast Cancer Novartis Pharmaceuticals|Translational Research in Oncology|Novartis December 7 2018 Phase 3
NCT03613220 Completed Drug: ribociclib|Drug: letrozole HR+ HER2 Breast Cancer Novartis Pharmaceuticals|Novartis December 28 2018 Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

CDK Signaling Pathway Map

Related CDK Products

Tags: buy Ribociclib (LEE011) | Ribociclib (LEE011) supplier | purchase Ribociclib (LEE011) | Ribociclib (LEE011) cost | Ribociclib (LEE011) manufacturer | order Ribociclib (LEE011) | Ribociclib (LEE011) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID